Drug Industry Urges Caution Over Japan HTA Plans
This article was originally published in SRA
Executive Summary
Japan's Ministry of Health, Labour and Welfare has decided on a pilot health technology assessment (HTA) program to be initiated in 2016, which will be applied initially only to a limited number of existing approved drugs.
You may also be interested in...
EFPIA Urges Japan To Consider New Funding Models
Amid intensifying official scrutiny of rising drug costs, the European industry federation EFPIA would like Japan to focus more on the measuring the actual benefits and health outcomes of new therapies, helped by new approaches and technology.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.